Overall impact
B (65)

Commentary

Quidel is a strong overall performer. With a 'B' rating of 65.1 for overall impact (73rd percentile compared to all companies), Quidel ranks 15th out of 22 industry peers, behind Amag Pharmaceuticals, Fluoropharma Medical, Aspira Women’s Health and 11 others, and ahead of OncoCyte, Quotient, DBV Technologies and 4 others. On top material causes for Quidel's industry (Pharmaceuticals & Biotech), Quidel performs well in Child and Maternal Health (86.9 score) and Disease Eradication (96.4) and performs poorly in Fair Labor Practices (38.1 score) and Reduced Inequality (38.1).
Impact
Cause QDEL
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
6,500
Sector
Health Care
Industry
Life Sciences Tools & Services
Sub-industry
Health Care Equipment
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ca, United States
Share classes
TEMP.55ca33ea
QDEL
Description
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Material causes
Ethos considers the following causes material for Quidel, based on its industry sub-industry Health Care Equipment. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.